Lifecare ASA · OSL:LIFE
Lifecare ASA — Investor Presentation (June 2022)
29 slides from Lifecare ASA's investor presentation, June 2022
Slide 1: Lifecare investor presentation June 2022
Lifecare investor presentation June 2022
Slide 2: Disclaimer
Disclaimer The information in this presentation has been prepared by Lifecare (the “Company”). This presentation does not constitute a recommendation regarding any securities of the Company. By accepting to attend this presentation and/or receive this information, you agree to be bound by the follow
Slide 3: Content overview
Content overview Why invest in Lifecare Lifecare organization Investment highlights 3
Slide 4: Why invest in Lifecare
Why invest in Lifecare Risk reducing factor Diabetes Lifecare is a sensor company developing “Sencell”, the smallest injectable Continuous • Chronic disease - occurs either when the pancreas does not Glucose Monitoring sensor in the world. Our proprietary osmotic sensing technology will help produce
Slide 5: Take control – take care
Take control – take care Inject and Long term use and no body worn forget devices Convenient and Lower cost of care simple in use Actionable data Higher sensitivity Maintain control Improved quality of life 5
Slide 6: Diabetes market growing
Diabetes market growing Attractive market outlook Number of adults (20-79) living with diabetes ✓ 11,5% of global health expenditure is 783 Millions spent on diabetes - USD 966 billion (2045) ✓ 1 in 10 adults worldwide live with 643 millions diabetes - 537 million people (2030) ✓ 541 million people
Slide 7: Potential target patient population
Potential target patient population Regions Population Primary Primary Total targeted by with Target Type Target Type target Lifecare diabetes 1 (T1DM) 2 (T2DM) population EU, EEA, UK, 36 Mill 2,3 Mill 6,3 Mill 8,6 Mill CH US, CA 51 Mill 2,7 Mill 7,2 Mill 9,9 Mill High Income 29 Mill 2,1 Mill 5,6 Mi
Slide 8: Sencell Market Potential
Sencell Market Potential The basis for the market potential is described in the document “SENCELL Market Assumptions and Commercial Potential, April 2022» available for downloading at www.lifecare.no Assuming lower cost and longevity, accurate and user-friendly measurements - indicates potential to
Slide 9: Sencell – Potential Revenue Calculation
Sencell – Potential Revenue Calculation Market penetration Sencell Base Case 2024 2025 2026 2027 2028 2029 2030 Level of assumed market penetration - base case EU, UK, EEA and CH 5% 20 % 40 % 80 % 95 % 100 % 100 % US and CA 0% 0% 10 % 30 % 50 % 75 % 95 % AU, CL, IL, JP, KR, KW, NZ, OM, QA, SA, SG, T
Slide 10: Content overview
Content overview Why invest in Lifecare Lifecare organization Investment highlights 10
Slide 11: Highly skilled and experienced team
Highly skilled and experienced team World class expertise in diabetes medicine and technology Prof. David Klonoff Prof. Lutz Heinemann Joacim Holter Prof. Andreas Pfützner Scientific Advisory Board Bo Petersson Board of Directors CEO CSO Chairman Board of Directors Scientific Advisory Board • LL.M f
Slide 12: Organization
Organization • Patent owner • Listed on Oslo Euronext Stock Exchange («Life») Main office and administration Bergen (NO) 100% 100% Sensor validation & evaluation Mems & Sensor Research Mainz (DE) Tübingen (DE) 12
Slide 13: Content overview
Content overview Why invest in Lifecare Lifecare organization Investment highlights 13
Slide 14: Sencell – a contributor to solve the diabetes pandemic
Sencell – a contributor to solve the diabetes pandemic Affordable to more patients Lower Cost Reduced public health costs Osmotic pressure correlates Accurate 100% with glucose levels No calibration needed, inject and User friendly forget Miniature sensor injected under Invisible the skin Continous
Slide 15: Patented technology
Patented technology • Composition of membranes Double membrane patent • A pressure sensor with a chamber on each side, where the two chambers have individual semi- 2004-2024 permeable membranes • Valid 2024 Augmented osmotic pressure patent • Apparatus for measuring augmented osmotic pressure • Pate
Slide 16: Technology – Osmosis
Technology — Osmosis m »)) Transfer of data (« © Power supply € Con A @ Dextran @ Glucose (1) * Glucose molecule Ce) LIFECARE
Slide 17: Technology – Osmotic pressure
Technology – Osmotic pressure Osmotically active particles – captured in chamber by size Closed osmotic pressure chamber Osmotic pressure correlates 100% with glucose levels Pressure sensor detects glucose variations 17
Slide 18: Technology – Sencell model
Technology – Sencell model A small body device containing pressure membrane, active chamber, pressure sensor, microelectronics and wireless communication 18
Slide 19: Technology – accurate and continous
Technology – accurate and continous Overview in electron microscope: Osmotic pressure sensors - sensor element printed to electrode by a controlled 3d nanoprinting process Membrane area 7 µm 500 µm 200 µm 20 µm Electrode for <1 µm gap between Electrode position at 3D printed 4x1 µm² nanosensor acces
Slide 20: Technology - Sencell Needle Sensor
Technology - Sencell Needle Sensor 1,3 8 4,7 20
Slide 21: Major milestones
Major milestones ✓ In-vitro testing of basic technology: osmotic pressure, chemistry ✓ Pre-clinical tests with basic technology: single chamber measurement ✓ Pre-Clinical tests with improved technology: dual chamber measurement ✓ Miniaturization of sensing element – shrinking the product to a grain
Slide 22: Clinical studies
Clinical studies • Wired Needle Sensor LFS-SEN-001 • 15 participants (10 healthy subjects & 5 patients with T1D • 3 days / proof of concept in humans • Implanted Encapsulated Wireless Sensor • 50 patients with type 1 or type 2 diabetes LFS-SEN-002 • 3 months • System performance + biocompatibility •
Slide 23: Valuedriven Future Milestones
Valuedriven Future Milestones Lifecare Sencell Conduct Prototype human clinical Conduct Market launch fabrication for trials – pilot human clinical CE mark through clinical trials study trials partnering 1H 2022 1H 2022 2H 2022 1H 2023 2H 2023 LFS-SEN-001 LFS-SEN-002 LFS-SEN-002 LFS-SEN-003 FDA LFS-
Slide 24: Risk factors
Risk factors delay due to prolonged delay due to pandemic delay due to (unforeseen) Increased costs of raw delivery timelines of sensor developments new regulatory materials and third party components requirements suppliers 24
Slide 25: Multiple potential products
Multiple potential products Pipeline has potentially multiple therapeutic areas Chemistry giving the opportunity to expand product areas in combination with Sencell – use it is a platform technology Several patents in preparation 25
Slide 26: Product development agreement Sanofi
Product development agreement Sanofi Sanofi-Avenis Group sponsor the development program for miniaturizing the Sencell Glucose sensor with funding of EUR 290.000 based on completion of defined development phases The Development Agreement is based on a robust evaluation and due diligence process from
Slide 27: FORGETDIABETES - A radically new approach to diabetes treatment
FORGETDIABETES - A radically new approach to diabetes treatment Uniquely capable to Create a bionic exploit physiological glucose sensing and pancreas hormones delivery route Lifecare is the selected enabling partner and the only intraperitoneal Optimising glycaemic control commercial partner in ins
Slide 28: FORGETDIABETES - A radically new approach to diabetes treatment
FORGETDIABETES - A radically new approach to diabetes treatment www.forgetdiabetes.eu 28
Slide 29: © LIFECARE
© LIFECARE